AXSM Q3 2022 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M

Gross Profit

$15M88.6% margin

Operating Income

-$42M-251.8% margin

Net Income

-$45M-266.1% margin

EPS (Diluted)

$-1.07

QoQ Revenue Growth

+91.0%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$339M

Total Liabilities

$182M

Stockholders' Equity

$157M

Cash & Equivalents

$228M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$0	—
Gross Profit	$15M	$0	—
Operating Income	-$42M	-$33M	-27.0%
Net Income	-$45M	-$35M	-28.5%